Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

ABSTRACT: IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

PROVIDER: PRJNA606620 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

Project description:IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

| PRJNA606621 | ENA

Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine

Project description:This SuperSeries is composed of the following subset Series: GSE29996: Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine [Affymetrix SNP array data] GSE29998: Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine [Illumina mRNA expression array data] Refer to individual Series

2012-10-25 | E-GEOD-29999 | biostudies-arrayexpress

Genomic Medicine and Gene Function Implementation for an Underserved Population

Project description:Genomic Medicine and Gene Function Implementation for an Underserved Population

| PRJNA836687 | ENA

Genomic Medicine and Gene Function Implementation for an Underserved Population

Project description:Genomic Medicine and Gene Function Implementation for an Underserved Population

| PRJNA836686 | ENA

Patient-Derived Models of Prostate Cancer for Personalized Medicine

Project description:Patient-Derived Models of Prostate Cancer for Personalized Medicine

| PRJNA1018661 | ENA

PAGE: The Charles Bronfman Institute for Personalized Medicine (IPM) BioMe Biobank

Project description:PAGE: The Charles Bronfman Institute for Personalized Medicine (IPM) BioMe Biobank

| PRJNA285518 | ENA

Reprograming human fibroblasts into Sertoli cells: a tool for personalized medicine

Project description:Reprograming human fibroblasts into Sertoli cells: a tool for personalized medicine

| PRJNA1032086 | ENA

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma [MethArray_5days]

Project description:The heterogenous genomic nature of most sarcoma subtypes makes them especially indicated for personalized treatment approaches. Here, we developed a personalized medicine strategy based in the use of patient-derived cell lines as a drug-testing platform. Targeted sequencing of a panel of cancer-related genes in these models revealed the presence of IDH1 and IDH2 mutations in two chondrosarcomas. Mutant IDH (mIDH) enzymes produce the oncometabolite 2-HG which contributes to driving tumor growth. Thus, we treated several chondrosarcoma models with specific mIDH1/2 inhibitors. Among these treatments, only the mIDH2 inhibitor enasidenib was able to decrease 2-HG levels and to efficiently reduce the viability of mIDH2 chondrosarcoma cells. Importantly, oral administration of enasidenib in xenografted mice resulted in a complete abrogation of tumor growth. Enasidenib induced a profound remodeling of the transcriptomic landscape not associated to changes in the 5mC methylation levels and its anti-tumor effects were associated to the repression of proliferative pathways such as those controlled by E2F factors. Overall, this work provides the first preclinical evidence for the use of enasidenib to treat mIDH2 chondrosarcomas.

2024-03-12 | GSE261421 | GEO

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma [RNAseq_Enasidenib_L2975_SW1353]

2024-03-13 | GSE261434 | GEO

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma [MethArray_2days]

2024-03-11 | GSE235697 | GEO